Literature DB >> 33775832

Inflammation, negative affect, and amyloid burden in Alzheimer's disease: Insights from the kynurenine pathway.

Auriel A Willette1, Colleen Pappas2, Nathan Hoth2, Qian Wang2, Brandon Klinedinst3, Sara A Willette2, Brittany Larsen3, Amy Pollpeter4, Tianqi Li4, Scott Le2, Ana D Collazo-Martinez2, Jonathan P Mochel5, Karin Allenspach6, Robert Dantzer7.   

Abstract

BACKGROUND: Depressive symptoms in Alzheimer's disease (AD) predict worse cognitive and functional outcomes. Both AD and major depression inflammatory processes are characterized by shunted tryptophan metabolism away from serotonin (5-HT) and toward the neuroinflammatory kynurenine (Kyn) pathway. The present study assessed associations between Kyn and behavioral, neuroanatomical, neuropathological, and physiological outcomes common to both AD and negative affect across the AD continuum.
METHODS: In 58 cognitively normal, 396 mild cognitive impairment, and 112 AD participants from the Alzheimer's Disease Neuroimaging Initiative-1 (ADNI1) cohort, serum markers of 5-HT, tryptophan, and Kyn were measured and their relationships investigated with immunologic markers, affect and functional outcomes, CSF markers of beta-amyloid (Aβ) and tau, and regional gray matter.
RESULTS: A higher Kyn/Tryptophan ratio was linked to many inflammatory markers, as well as lower functional independence and memory scores. A higher Kyn/5-HT ratio showed similar associations, but also strong relationships with negative affect and neuropsychiatric disturbance, executive dysfunction, and global cognitive decline. Further, gray matter atrophy was seen in hippocampus, anterior cingulate, and prefrontal cortices, as well as greater amyloid and total tau deposition. Finally, using moderated-mediation, several pro-inflammatory factors partially mediated Kyn/5-HT and negative affect scores in participants with subclinical Aβ (i.e., Aβ-), whereas such associations were fully mediated by Complement 3 in Aβ+ participants.
CONCLUSION: These findings suggest that inflammatory signaling cascades may occur during AD, which is associated with increased Kyn metabolism that influences the pathogenesis of negative affect. Aβ and the complement system may be critical contributing factors in this process.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; Depression; Inflammation; Kynurenine; Serotonin; Tryptophan

Mesh:

Substances:

Year:  2021        PMID: 33775832      PMCID: PMC8187283          DOI: 10.1016/j.bbi.2021.03.019

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   19.227


  69 in total

1.  A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment.

Authors:  Laura E Gibbons; Adam C Carle; R Scott Mackin; Danielle Harvey; Shubhabrata Mukherjee; Philip Insel; S McKay Curtis; Dan Mungas; Paul K Crane
Journal:  Brain Imaging Behav       Date:  2012-12       Impact factor: 3.978

2.  Insulin resistance predicts brain amyloid deposition in late middle-aged adults.

Authors:  Auriel A Willette; Sterling C Johnson; Alex C Birdsill; Mark A Sager; Bradley Christian; Laura D Baker; Suzanne Craft; Jennifer Oh; Eric Statz; Bruce P Hermann; Erin M Jonaitis; Rebecca L Koscik; Asenath La Rue; Sanjay Asthana; Barbara B Bendlin
Journal:  Alzheimers Dement       Date:  2014-07-17       Impact factor: 21.566

3.  Inflammation and interleukin-1 signaling network contribute to depressive symptoms but not cognitive decline in old age.

Authors:  Anita H J van den Biggelaar; Jacobijn Gussekloo; Anton J M de Craen; Marijke Frölich; Max L Stek; Roos C van der Mast; Rudi G J Westendorp
Journal:  Exp Gerontol       Date:  2007-02-04       Impact factor: 4.032

4.  Acute inflammation and negative mood: mediation by cytokine activation.

Authors:  C E Wright; P C Strike; L Brydon; A Steptoe
Journal:  Brain Behav Immun       Date:  2004-12-08       Impact factor: 7.217

5.  Investigation of interobserver reliability of the Gillette Functional Assessment Questionnaire in children with spastic diparetic cerebral palsy.

Authors:  Mintaze Kerem Günel; Tülay Tarsuslu; Akmer Mutlu; Ayşe Livanelioğlu
Journal:  Acta Orthop Traumatol Turc       Date:  2010       Impact factor: 1.511

6.  Quinolinic acid upregulates chemokine production and chemokine receptor expression in astrocytes.

Authors:  Gilles J Guillemin; Juliana Croitoru-Lamoury; Dominique Dormont; Patricia J Armati; Bruce J Brew
Journal:  Glia       Date:  2003-03       Impact factor: 7.452

7.  Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer.

Authors:  Yuzo Suzuki; Takafumi Suda; Kazuki Furuhashi; Masako Suzuki; Michio Fujie; Dai Hahimoto; Yutaro Nakamura; Naoki Inui; Hirotoshi Nakamura; Kingo Chida
Journal:  Lung Cancer       Date:  2009-05-31       Impact factor: 5.705

8.  Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder.

Authors:  Timothy B Meier; Wayne C Drevets; Brent E Wurfel; Bart N Ford; Harvey M Morris; Teresa A Victor; Jerzy Bodurka; T Kent Teague; Robert Dantzer; Jonathan Savitz
Journal:  Brain Behav Immun       Date:  2015-11-04       Impact factor: 7.217

Review 9.  Overview of depression and psychosis in Alzheimer's disease.

Authors:  R E Wragg; D V Jeste
Journal:  Am J Psychiatry       Date:  1989-05       Impact factor: 18.112

10.  Microglial activation and tau burden predict cognitive decline in Alzheimer's disease.

Authors:  Maura Malpetti; Rogier A Kievit; Luca Passamonti; P Simon Jones; Kamen A Tsvetanov; Timothy Rittman; Elijah Mak; Nicolas Nicastro; W Richard Bevan-Jones; Li Su; Young T Hong; Tim D Fryer; Franklin I Aigbirhio; John T O'Brien; James B Rowe
Journal:  Brain       Date:  2020-05-01       Impact factor: 13.501

View more
  5 in total

Review 1.  Kynurenine Metabolism and Alzheimer's Disease: The Potential Targets and Approaches.

Authors:  Vivek Kumar Sharma; Thakur Gurjeet Singh; Nirbhay Kumar Prabhakar; Ashi Mannan
Journal:  Neurochem Res       Date:  2022-02-08       Impact factor: 3.996

Review 2.  Kynurenine Pathway Metabolites as Biomarkers in Alzheimer's Disease.

Authors:  Yuqing Liang; Shan Xie; Yanyun He; Manru Xu; Xi Qiao; Yue Zhu; Wenbin Wu
Journal:  Dis Markers       Date:  2022-01-19       Impact factor: 3.434

3.  Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis.

Authors:  Mobina Fathi; Kimia Vakili; Shirin Yaghoobpoor; Arian Tavasol; Kimia Jazi; Ramtin Hajibeygi; Sina Shool; Fatemeh Sodeifian; Andis Klegeris; Alyssa McElhinney; Mostafa Rezaei Tavirani; Fatemeh Sayehmiri
Journal:  Front Immunol       Date:  2022-10-03       Impact factor: 8.786

Review 4.  Punicalagin Regulates Signaling Pathways in Inflammation-Associated Chronic Diseases.

Authors:  Jie Xu; Ke Cao; Xuyun Liu; Lin Zhao; Zhihui Feng; Jiankang Liu
Journal:  Antioxidants (Basel)       Date:  2021-12-24

Review 5.  Alzheimer's disease biomarkers in Black and non-Hispanic White cohorts: A contextualized review of the evidence.

Authors:  Carey E Gleason; Megan Zuelsdorff; Diane C Gooding; Amy J H Kind; Adrienne L Johnson; Taryn T James; Nickolas H Lambrou; Mary F Wyman; Fred B Ketchum; Alexander Gee; Sterling C Johnson; Barbara B Bendlin; Henrik Zetterberg
Journal:  Alzheimers Dement       Date:  2021-12-06       Impact factor: 16.655

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.